Cureus
Cure8 research brief
Why This Matters
People with IBD who also have bleeding disorders face special risks during endoscopy, surgery, and when using immunosuppressive drugs. This case shows that coordinated care and hemostatic support can allow diagnosis and treatment.
Who Should Pay Attention
Patients with Crohn disease and bleeding disorders, clinicians (gastroenterologists, surgeons, hematologists), caregivers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This 20-year-old patient with lifelong afibrinogenemia presented with bloody diarrhea and an active horseshoe anal fistula. Because of bleeding risk, fibrinogen concentrate was given before endoscopy and biopsies to establish the diagnosis.
After multidisciplinary discussion she was treated with infliximab plus azathioprine; her gastrointestinal and perianal symptoms improved and bleeding episodes (epistaxis) were controlled with fibrinogen replacement without major hemorrhagic, thrombotic, or infectious complications reported.
The report emphasizes individualized, multidisciplinary planning (gastroenterology, surgery, and hematology) and peri-procedural hemostatic support when invasive diagnostics or treatments are needed in patients with severe coagulation disorders.
Keep In Mind
Single-patient case report — useful for awareness and care planning but not proof of safety or efficacy for specific treatments in this rare combination.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCureus
AuthorsAyoub Bouziane, Ouiam Elmqaddam, Hajar Koulali +3 more
InstitutionDepartment of Gastroenterology and Hepatology, Mohammed VI University Hospital, Oujda, MAR.
Study typeCase reports, journal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 12, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Do You Need to Treat Asymptomatic Crohn’s Disease?
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
TNF inhibitors might help prevent serious complications in kids with Crohn's Disease
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.